Wall Street analysts generally classify Aurora Cannabis (ACB) with cautious "Hold" ratings, balancing its successful debt reduction and growing European medical cannabis sales against historical net losses, sector-wide headwinds, and continuous dilution risks. Investors must weigh speculative growth potential in medical markets against micro-cap cannabis volatility before deciding to buy or sell.